Bernard P, Abdallah A N, Marit G, David B, Broustet A, Reiffers J
Service des Maladies du Sang, CHR Bordeaux, France.
Nouv Rev Fr Hematol (1978). 1987;29(6):359-64.
Bone marrow karyotyping was serially performed in 23 Ph1+ chronic myelocytic leukemia patients treated with allogeneic bone marrow transplantation (BMT). Two patients underwent 2 BMT each. Fifteen patients had only normal karyotypes and 8 patients (after 10 BMT) had either sporadic Ph1+ metaphases (6 cases) or cytogenetic signs of relapse (4 cases, of which in 1 case, without hematological symptoms), or both in succession. Sporadic Ph1+ metaphases were found early after BMT (never after the 6th month). Although they were more frequent in non-splenectomized patients than in others, there was no significant correlation between sporadic Ph1+ metaphases and disease features, treatment regimens or evolution after BMT.
对23例接受异基因骨髓移植（BMT）治疗的Ph1+慢性粒细胞白血病患者进行了连续的骨髓核型分析。2例患者分别接受了2次BMT。15例患者的核型仅为正常，8例患者（在10次BMT后）出现散在的Ph1+中期分裂相（6例）或细胞遗传学复发迹象（4例，其中1例无血液学症状），或两者相继出现。散在的Ph1+中期分裂相在BMT后早期出现（6个月后从未出现）。虽然它们在未行脾切除术的患者中比在其他患者中更常见，但散在的Ph1+中期分裂相与疾病特征、治疗方案或BMT后的病情演变之间无显著相关性。
